Request an appointment
Your path to clearer, brighter cognitive health begins here—with expert care, genuine warmth, and unwavering support. Contact us or request a call back today.
Why Brain Imaging Matters in Memory Disorders
If you or a loved one is experiencing memory problems, one of the first questions you may ask is: “Do I need a brain scan?” Brain imaging has become a cornerstone of modern dementia assessment. It can help rule out other causes of memory problems, such as strokes or tumours, and in many cases, it provides crucial insights into the underlying disease process.
But not all scans are equal. A standard MRI is usually the first step, yet a normal MRI does not rule out dementia. This is why advanced functional imaging — such as FDG PET, amyloid PET, and DAT scans — is sometimes needed to provide a clearer picture.
MRI: The First-Line Structural Scan
MRI (magnetic resonance imaging) is the backbone of dementia workup. It shows the structure of the brain, allowing doctors to:
- Detect strokes, tumours, or fluid build-up.
- Identify shrinkage (atrophy) in memory-related regions like the hippocampus.
- Rule out other treatable conditions that mimic dementia.
However, MRI has an important limitation: it only shows damage once brain cells have already died. In the early stages of Alzheimer’s or Lewy body dementia, the brain may look structurally normal on MRI.
That’s why a normal MRI does not mean there is no dementia. Instead, it may simply mean the disease is at a stage where more advanced testing is required.
Functional Brain Imaging: Looking Beyond Structure
Functional imaging goes a step further. Rather than showing what the brain looks like, it shows how the brain is working. These scans can detect abnormal protein build-up, altered metabolism, or disrupted brain pathways — often years before changes appear on MRI.
Amyloid PET: Detecting Alzheimer’s Pathology
- What it shows: Amyloid PET scanning detects the build-up of amyloid plaques — a hallmark of Alzheimer’s disease.
- When it’s useful: Particularly valuable in patients with mild cognitive impairment (MCI) or subtle symptoms when the MRI is normal. It provides biomarker evidence of Alzheimer’s disease, confirming the diagnosis at a much earlier stage.
- Limitations: Amyloid deposition increases with age, even in some people without dementia. This makes it most useful in younger patients with suspicious symptoms, where a positive scan is much more likely to reflect true Alzheimer’s pathology.
FDG PET: Seeing Changes Before Cell Death
- What it shows: FDG PET measures glucose metabolism across brain regions. Because nerve cells rely on glucose, areas of reduced metabolism (hypometabolism) indicate dysfunction — even if no structural changes are visible yet.
- Clinical patterns:
- Alzheimer’s disease → reduced metabolism in temporal and parietal lobes.
- Frontotemporal dementia → frontal and anterior temporal changes.
- Lewy body dementia → occipital involvement.
- Why it matters: FDG PET can reveal upstream functional changes that MRI misses, making it particularly powerful when early symptoms are present but MRI appears normal.
DAT Scan: Assessing the Dopamine Pathway
- What it shows: A DAT (dopamine transporter) scan looks at the integrity of the nigrostriatal dopamine pathway, which is affected in Parkinson’s disease and dementia with Lewy bodies (DLB).
- When it’s useful: Helps distinguish parkinsonian dementias (Parkinson’s disease dementia, DLB) from non-parkinsonian causes of memory loss.
- Limitations: In up to 10% of patients with DLB, the DAT scan can still appear normal. Early Parkinson’s disease can also produce a normal result.
- Why expertise matters: Parkinsonian dementias are the second most common cause of dementia after Alzheimer’s, yet they are often misdiagnosed or overlooked — sometimes by psychiatrists in memory clinics, and even by general neurologists without a movement disorder focus. This is why expert interpretation is critical.
The Evolving Role of Blood Biomarkers
In addition to imaging, new blood tests are transforming dementia diagnostics. The LucentAD® blood test, for example, measures proteins linked to Alzheimer’s disease, providing a minimally invasive biomarker to support diagnosis.
This test is used at our clinic when appropriate, as it provides precision and allows for earlier detection of Alzheimer’s pathology. However, like scans, blood biomarkers are not definitive on their own. They must be interpreted within the wider clinical context — by a clinical expert who has seen the patient, who knows their story, and who can place the result in its proper perspective.
The Bigger Picture: Why Tests Alone Are Never Enough
As dementia diagnostics evolve, we are moving steadily towards ever more advanced tools — from biomarker-based blood tests like LucentAD®, to highly sensitive functional imaging techniques. These advances give us unprecedented insight into the earliest brain changes in conditions such as Alzheimer’s, Lewy body dementia, and frontotemporal dementia.
But there is one truth that never changes: a test can never stand alone.
Every scan — whether MRI, FDG PET, amyloid PET, or DAT — must be interpreted against the backdrop of the patient’s symptoms, history, and examination. Without that integration, the results can mislead rather than clarify.
This is why the backbone of memory assessment is still the clinical expert. At our clinic, advanced diagnostics are integrated into carefully designed pathways, but always anchored by expert interpretation.
In short: the technology informs — but the expert decides.
Key Takeaways
- A normal MRI does not rule out dementia.
- Functional scans (amyloid PET, FDG PET, DAT) provide vital insights when MRI is inconclusive.
- Each modality has strengths and limitations; none are definitive alone.
- New blood biomarkers (e.g., LucentAD®) are expanding diagnostic possibilities.
- The clinical expert remains at the centre — tests are tools, not replacements.
About the Author
This article was written and reviewed by Dr Soumit Singhai FRCP, Consultant Geriatrician and Founder of the Memory & Brain Clinic London. Dr Singhai has over two decades of experience in diagnosing and treating memory disorders, including Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Known for his compassionate, patient-centred approach, he combines the latest diagnostic tools — from advanced imaging to biomarker blood tests — with expert clinical judgment to provide clarity and reassurance for patients and families.
